LISINOPRIL TABLETS

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

LISINOPRIL (LISINOPRIL DIHYDRATE)

可用日期:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC代码:

C09AA03

INN（国际名称）:

LISINOPRIL

剂量:

20MG

药物剂型:

TABLET

组成:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0121550002; AHFS:

授权状态:

APPROVED

授权日期:

2009-08-20

产品特点

_ _
_Page 1 of 41_
PRODUCT MONOGRAPH
PR
LISINOPRIL TABLETS
(LISINOPRIL)
5 mg, 10 mg and 20 mg of lisinopril as lisinopril dihydrate
USP
Angiotensin Converting Enzyme Inhibitor
Ranbaxy Pharmaceuticals Canada Inc.
2680 Matheson Blvd East, Suite 200
Mississauga, Ontario
L4W 0A5
Date of Preparation:
August 17, 2009
Submission Control No: 131981
_ _
_ _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND
ADMINISTRATION.............................................................................
18
OVERDOSAGE
...............................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 21
STORAGE AND
STABILITY.........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
..............................................................................
25
PHARMACEUTICAL
INFORMATION.........................................................................
25
CLINICAL
TRIALS.........................................................................................................
26
DETAILED
PHARMACOLOGY